Development asset linked to Keros Therapeutics in public FDA and regional records.
pharma · Pulmonary Arterial Hypertension · Iron Deficiency Anemia · KROS
Keros Therapeutics
Keros Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2021 Founded
10 Employees
Public company Type
KROS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2021
- Employees
- 10
- Programs
- 3
- Drugs
- 2
- Patents
- 12
Keros Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Keros Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Keros Therapeutics in public FDA and regional records.